Harrow (HROW) Total Non-Current Liabilities (2014 - 2024)
Harrow (HROW) posted quarterly Total Non-Current Liabilities of $291.2 million for Q3 2024, up 40.04% year-over-year from $208.0 million in Q4 2023, and up 18.5% quarter-over-quarter from $245.7 million in Q2 2024.
Harrow (HROW) Total Non-Current Liabilities (2014 - 2024) Analysis & Trends
Harrow's Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $291.2 million for Q3 2024.
- In Q3 2024, Total Non-Current Liabilities rose 40.04% year-over-year to $291.2 million; the TTM figure through Sep 2024 stood at $291.2 million (up 40.04% YoY), while the FY2023 annual figure was $239.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q3 2024 stood at $291.2 million, up from $245.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $291.2 million in Q3 2024, with the low at $27.6 million in Q1 2021.
- The 4-year median for Total Non-Current Liabilities is $196.7 million (2023), against an average of $147.1 million.
- The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities declined 11.21% in 2021, then surged 40.04% in 2024.
- Harrow's Total Non-Current Liabilities stood at $29.8 million in 2020, then retreated by 7.59% to $27.6 million in 2021, then soared by 766.65% to $239.0 million in 2023, then increased by 21.82% to $291.2 million in 2024.
- Business Quant data shows HROW's Total Non-Current Liabilities at $291.2 million in Q3 2024, $245.7 million in Q2 2024, and $232.6 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Harrow | 1.58 Bn | 1.49 Bn | 50.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 291.21 Mn |
| Jun 30, 2024 | 245.74 Mn |
| Mar 31, 2024 | 232.62 Mn |
| Dec 31, 2023 | 239.04 Mn |
| Sep 30, 2023 | 207.95 Mn |
| Jun 30, 2023 | 199.66 Mn |
| Mar 31, 2023 | 193.70 Mn |
| Mar 31, 2021 | 27.58 Mn |
| Dec 31, 2020 | 29.85 Mn |
| Sep 30, 2020 | 33.74 Mn |
| Jun 30, 2020 | 33.26 Mn |
| Mar 31, 2020 | 31.07 Mn |
| Dec 31, 2019 | 30.87 Mn |
| Sep 30, 2019 | 30.17 Mn |
| Jun 30, 2019 | 29.36 Mn |
| Mar 31, 2019 | 28.68 Mn |
| Dec 31, 2018 | 23.90 Mn |
| Sep 30, 2018 | 23.04 Mn |
| Jun 30, 2018 | 21.80 Mn |
| Mar 31, 2018 | 20.32 Mn |